SMARCB1 and neoplasm: Numerous drugs aimed at these mutations have demonstrated encouraging outcomes in preclinical tumor models and clinical advancements include FDA-approved EZH2 inhibitors for cancers with SMARCB1 mutations and more targets are now identified through genome-wide screens for clinical trials (Malone and Roberts 2024).